Genetic Testing Market: Size, Share, Trends & Forecast (2024-2029) 

The market report presents a thorough analysis segmented by Type (Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Predictive and Presymptomatic Testing, Others); by Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing); by Application (Cancer Diagnosis, Genetic Disease diagnosis, Others); by Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa).

Outlook 

• The genetic testing market is estimated to be at USD 21,820.12 Mn in 2024 and is anticipated to reach USD 35,990.32 Mn in 2029. 

• The genetic testing market is registering a CAGR of 10.53% during the forecast period of 2024-2029. 

• The global genetic testing market is experiencing rapid growth, driven by advancements in genomics and increasing awareness of personalized medicine. Genetic testing involves analyzing an individual’s DNA to identify genetic variations that may lead to certain health conditions. The expanding application of genetic testing in prenatal screening, oncology, and rare diseases is also contributing to market expansion. 

Request a free sample. 

Ecosystem

• The participants in the global genetic testing industry are always developing their strategies to preserve a competitive advantage. 

• Continuous innovation is a hallmark of the genetic testing market. Companies are developing new tests and technologies, such as liquid biopsy tests and AI-driven genetic analysis, to stay competitive. 

• Several important entities in the genetic testing market include Danaher Corp.; Thermo Fisher Scientific Inc.; Qiagen N.V.; Bio-Rad Laboratories, Inc.; CSL Ltd.; and others. 

Ask for customization. 

Findings 

Attributes	Values
Historical Period	2018-2022
Base Year	2023
Forecast Period	2024-2029
Market Size (2024)	USD 21,820.12 Mn
Market Size (2029)	USD 35,990.32 Mn
Growth Rate	10.48% CAGR from 2024 to 2029
Key Segments	Type (Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Predictive and Presymptomatic Testing); Technology (Cytogenetic Testing, Biochemical Testing, Molecular Testing); Application (Cancer Diagnosis, Genetic Disease Diagnosis, Others); Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa)
Key Vendors	Danaher Corp.; Thermo Fisher Scientific Inc.; Qiagen N.V.; Bio-Rad Laboratories, Inc.; CSL Ltd.
Key Countries	The US; Canada; Mexico; Brazil; Argentina; Colombia; Chile; China; India; Japan; South Korea; The UK; Germany; Italy; France; Spain; Turkey; UAE; Saudi Arabia; Egypt; South Africa
Largest Market	North America

Get a free quote. 

Trends  

• Integration of Artificial Intelligence (AI) in Genetic Analysis: AI and machine learning are being integrated into genetic testing to enhance the accuracy and speed of data interpretation. These technologies help in analyzing large genomic datasets, identifying patterns, and predicting disease risk with greater precision. AI is also playing a role in developing personalized treatment plans based on an individual’s genetic profile. IBM Watson for Genomics is an AI-powered platform that analyzes genetic data from cancer patients to identify specific mutations and suggests personalized treatment options. 

• Emphasis on Genetic Data Privacy: With the expansion of genetic testing, safeguarding genetic data privacy has become a critical concern. As the volume of genetic data grows, both companies and regulatory bodies are implementing stricter measures to protect sensitive information. Companies are adopting advanced encryption and data anonymization techniques to secure genetic data. As public awareness of data privacy issues increases, ensuring robust protection of genetic information is essential for maintaining trust and encouraging broader acceptance of genetic testing technologies. 

• Advancements in Whole Genome Sequencing: Whole genome sequencing (WGS) is experiencing significant progress, directed by decreasing costs and improved technology, which enables a thorough analysis of an individual’s entire genetic code. The Illumina company is at the forefront of this advancement, refining WGS technology to make it more accessible and clinically relevant. 

Speak to analyst. 

Catalysts 

• Advancements in Genomic Technologies: The development of next-generation sequencing (NGS) and other genomic technologies has significantly reduced the cost of genetic testing, which makes it more accessible. This technological progress is enabling more comprehensive and accurate tests, driving market growth. 

• Growing Awareness of Personalized Medicine: There is an increasing emphasis on personalized medicine, which tailors medical treatment to the individual characteristics of each patient. Genetic testing plays a critical role in this approach by providing insights into a person’s genetic predispositions, which leads to more effective and targeted therapies. 

• Rising Incidence of Genetic Disorders: The increasing prevalence of genetic disorders, such as cystic fibrosis, Huntington’s disease, and sickle cell anemia, is fueling the demand for genetic testing. Early detection through genetic testing allows for timely interventions, improving patient outcomes. 

Inquire before buying. 

Restraints 

• Potential for False Positives/Negatives: The reliability of genetic tests is paramount, yet the risk of false positives or negatives remains a significant concern. Such inaccuracies can lead to unnecessary stress, misguided medical decisions, or missed opportunities for early intervention. Addressing this issue requires continuous advancements in test precision, data interpretation, and validation to improve reliability and ensure patient trust in genetic testing. 

• High Cost of Genetic Testing: While technology has made genetic testing more accessible, the cost of comprehensive tests, particularly those involving whole-genome sequencing, remains high. This expense can be prohibitive, limiting access for individuals in low-income regions or those without adequate insurance coverage. As a result, disparities in healthcare access may persist, necessitating efforts to reduce costs and increase affordability. 

• Regulatory Challenges: Navigating the regulatory environment for genetic testing is complex, with significant variations across regions. Compliance with regulations such as those from the US FDA, the European Medicines Agency (EMA), or local regulatory bodies requires substantial investment in both time and resources. Companies must constantly adapt to evolving guidelines, which can be challenging and add to the overall cost of bringing new tests to market. 

Personalize this research. 

Hotspot 

Explore purchase options. 

Table of Contents 

1.       Introduction         1.1.    Research Methodology         1.2.    Scope of the Study  2.       Market Overview / Executive Summary         2.1.    Global Genetic Testing Market (2018 – 2022)         2.2.    Global Genetic Testing Market (2023 – 2029)  3.       Market Segmentation         3.1.    Global Genetic Testing Market by Type                3.1.1.    Carrier Testing                3.1.2.    Prenatal and Newborn Testing                3.1.3.    Diagnostic Testing                3.1.4.    Pharmacogenomic Testing                3.1.5.    Predictive and Presymptomatic Testing         3.2.    Global Genetic Testing Market by Technology                3.2.1.    Cytogenetic Testing                3.2.2.    Biochemical Testing                3.2.3.    Molecular Testing         3.3.    Global Genetic Testing Market by Application                3.3.1.    Cancer Diagnosis                3.3.2.    Genetic Disease Diagnosis                3.3.3.    Others  4.       Regional Segmentation         4.1.    North America                4.1.1.    The US                4.1.2.    Canada                4.1.3.    Mexico         4.2.    South America                4.2.1.    Brazil                4.2.2.    Argentina                4.2.3.    Colombia                4.2.4.    Chile                4.2.5.    Rest of South America         4.3.    Asia Pacific                4.3.1.    China                4.3.2.    India                4.3.3.    Japan                4.3.4.    South Korea                4.3.5.    Rest of Asia Pacific         4.4.    Europe                4.4.1.    The UK                 4.4.2.    Germany                4.4.3.    Italy                4.4.4.    France                4.4.5.    Spain                4.4.6.    Rest of Europe         4.5.    The Middle East                4.5.1.    Turkey                4.5.2.    UAE                4.5.3.    Saudi Arabia                4.5.4.    Rest of the Middle East         4.6.    Africa                4.6.1.    Egypt                4.6.2.    South Africa                4.6.3.    Rest of Africa  5.       Value Chain Analysis of the Global Genetic Testing Market  6.       Porter Five Forces Analysis         6.1.    Threats of New Entrants         6.2.    Threats of Substitutes         6.3.    Bargaining Power of Buyers         6.4.    Bargaining Power of Suppliers         6.5.    Competition in the Industry  7.       Trends, Drivers and Challenges Analysis         7.1.    Market Trends         7.1.1.    Market Trend 1         7.1.2.    Market Trend 2         7.1.3.    Market Trend 3         7.2.    Market Drivers         7.2.1.    Market Driver 1         7.2.2.    Market Driver 2         7.2.3.    Market Driver 3         7.3.    Market Challenges         7.3.1.    Market Challenge 1         7.3.2.    Market Challenge 2         7.3.3.    Market Challenge 3  8.       Opportunities Analysis         8.1.    Market Opportunity 1         8.2.    Market Opportunity 2         8.3.    Market Opportunity 3  9.       Competitive Landscape         9.1.    Danaher Corp.         9.2.    Thermo Fisher Scientific Inc.         9.3.    Qiagen N.V.         9.4.    Bio-Rad Laboratories, Inc.         9.5.    CSL Ltd.         9.6.    Company 6         9.7.    Company 7         9.8.    Company 8         9.9.    Company 9         9.10.  Company 10

Know the research methodology. 

Genetic Testing Market – FAQs 

1.  What is the current size of the genetic testing market? 

Ans. In 2024, the genetic testing market size is USD 21,820.12 Mn. 

2.  Who are the major vendors in the genetic testing market?  

Ans. The major vendors in the genetic testing market are Danaher Corp.; Thermo Fisher Scientific Inc.; Qiagen N.V.; Bio-Rad Laboratories, Inc.; CSL Ltd. 

3.  Which segments are covered under the genetic testing market segments analysis?  

Ans. The genetic testing market report offers in-depth insights into Type, Technology, Application, and Geography.